Recent Updates
Recently added Catalysts
EBS Positive Sentiment

Emergent s Statement Regarding its Amended Credit Agreement GAITHERSBURG, Md.

Key Takeaway: Emergent BioSolutions (NYSE: EBS) has amended and extended the maturity of its existing syndicated credit agreement, aiming to stabilize and strengthen its core business. This move follows organizational changes and the recent sale of its travel health business to Bavarian Nordic. The company is optimistic about its strategy for sustainable growth and enhancing financial stability, enabling better focus on commitments, including the launch of the NARCAN Nasal spray.
Price reaction · baseline $8.87 (2023-05-16 close) · hit after-hours · clean, no other EBS news in the window
day 0 close · peak
+1.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • Amended credit agreement provides extended maturity and stability.
  • Focus on sustainable long-term growth following reorganization.
  • Increased certainty around financial obligations allows for commitment delivery.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+70%
120-day peak, hindsight
Typical move
8%
average across 2 past catalysts
Lead asset
FLU-IGIV
Phase 2 · Influenza A H3N2

Full Press Release Details

Emergent s Statement Regarding its Amended Credit Agreement
GAITHERSBURG, Md., May 17, 2023 Emergent (NYSE: EBS) completed an amendment and extension of maturity of its existing syndicated credit agreement
on May 15, 2023. We believe this revised structure and extended maturity furthers our ability to execute on our strategy to stabilize and strengthen our core business and position Emergent for sustainable long-term growth. It follows our successful
completion of organizational changes announced in January and the close of the sale of Emergent s travel health business to Bavarian Nordic on May 15.
Our amended credit facility represents another important step forward as we continue to strengthen our core businesses and build the foundation for
sustainable, long-term growth, said Emergent CFO Richard S. Lindahl. Working constructively with our bank group, we have now meaningfully extended our debt maturities and maintained our access to capital as we execute on our sharpened
With increased certainty regarding our financial obligations, we can increase our focus on delivering on our commitments to the
U.S. government, preparing for the launch of over-the-counter NARCAN Nasal spray, and further strengthening our quality and compliance culture and systems.
Safe Harbor Statement
This communication may include
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact are forward-looking statements. You should not unduly rely on any forward-looking
statements, which speak only as of the date of this communication. Investors should consider this cautionary statement, as well as the risk factors identified in our periodic reports filed with the Securities and Exchange Commission, when evaluating
forward-looking statements.
Director, Media Relations

Frequently Asked Questions

What did Emergent announce on May 15, 2023?

Emergent announced an amendment and extension of its syndicated credit agreement.

How does the amended credit facility benefit Emergent?

It strengthens core businesses and supports sustainable long-term growth.

Who commented on the credit facility amendment at Emergent?

Emergent CFO Richard S. Lindahl provided commentary on the amendment.

What is a focus for Emergent following the credit agreement amendment?

Emergent aims to prepare for the launch of NARCAN Nasal spray.

What should investors consider about forward-looking statements?

Investors should evaluate risks and not rely solely on forward-looking statements.

Last updated: May 17, 2023